Evidence map›Paper›PMID 36348308›Full record

ArticleBMC pediatrics2022

Two cases of infantile-onset primary generalized glucocorticoid hypersensitivity and the effect of mifepristone.

Xiu Zhao, Zhongwei Xu, Huiping Su, Rongfei Zheng, Min Zhan, Yuge Huang, Zhe Su

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Xiu ZhaoDepartment of Endocrinology, Shenzhen Children's Hospital, 7019# Yitian Road, Futian District, Shenzhen, 518038, Guangdong Province, China.
Zhongwei XuDepartment of Endocrinology, Shenzhen Children's Hospital, 7019# Yitian Road, Futian District, Shenzhen, 518038, Guangdong Province, China.
Huiping SuDepartment of Endocrinology, Shenzhen Children's Hospital, 7019# Yitian Road, Futian District, Shenzhen, 518038, Guangdong Province, China.
Rongfei ZhengDepartment of Endocrinology, Shenzhen Children's Hospital, 7019# Yitian Road, Futian District, Shenzhen, 518038, Guangdong Province, China.
Min ZhanPharmacy Department, Shenzhen Children's Hospital, Shenzhen, 518000, Guangdong Province, China.
Yuge HuangDepartment of Pediatrics, the Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524023, Guangdong, China.
Zhe SuDepartment of Endocrinology, Shenzhen Children's Hospital, 7019# Yitian Road, Futian District, Shenzhen, 518038, Guangdong Province, China. su_zhe@126.com.
Shenzhen Children's Hospital · CNGuangdong Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary generalized glucocorticoid hypersensitivity (PGGH) is a very rare disease caused by terminal organ hypersensitivity to glucocorticoids for which the aetiology is unknown. The incidence of PGGH is extremely rare, especially in children. To date, the literatures about the etiology, prognosis and treatment of PGGH are scarce. Aim of the study is describing the cases of two Chinese children with infantile-onset PGGH in one family, one of whom died and one who was treated with mifepristone. They are the two youngest children with PGGH reported in the literature. CASE PRESENTATION: Two siblings with infantile-onset PGGH were affected in this family. The main manifestations of patient 1 were typical Cushing's syndrome-like manifestations, significantly aggravated symptoms after physiological doses of glucocorticoids and very low levels of serum cortisol and adrenocorticotropin hormone (ACTH) during attacks. After being diagnosed with PGGH, he was given guidance to avoid glucocorticoids and took mifepristone therapy for 5 months, and his symptoms improved. Patient 2 was the younger brother of patient 1, with similar manifestations to his brother at the age of 4 months. Patient 2 ultimately died at the age of 9 months.

conclusionPGGH is a very rare disease that can lead to death if not diagnosed and treated in a timely manner. This article describes the cases of the two youngest children with PGGH reported in the literature, one of whom improved after mifepristone treatment, and increases the knowledge of the clinical manifestations of and the treatment experience in PGGH.

Indexed as

Cushing SyndromeHypersensitivityAdrenocorticotropic HormoneChildGlucocorticoidsHumansInfantMaleMifepristoneRare DiseasesAdrenocorticotropic HormoneGlucocorticoidsMifepristoneCushing syndromeGlucocorticoidsMifepristonePrimary generalized glucocorticoid hypersensitivity

Identifiers

PMID36348308
PMCPMC9641862
OpenAlexW4308572500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.